Anti-MAG Neuropathy: PowerPoint Summary
Definition
Anti-MAG neuropathy is a rare IgM-mediated autoimmune demyelinating peripheral neuropathy caused by antibodies against myelin-associated glycoprotein, typically associated with monoclonal gammopathy of undetermined significance (MGUS) or Waldenström's macroglobulinemia. 1
Pathophysiology
The disease is driven by IgM paraprotein antibodies that directly target MAG on peripheral nerve myelin, causing distal-predominant demyelination. 1
- IgM antibodies bind to MAG on the outermost myelin lamellae
- Results in characteristic "widely spaced myelin" on electron microscopy
- Approximately 90% of cases harbor the MYD88L265P mutation 2
- Sulfated glucuronyl paragloboside antibodies may also be detected 1
- Disease progression is variable: some cases remain indolent for years/decades, others show acute accelerations 1
Clinical Presentation
The typical presentation is a predominantly sensory ataxic symmetric demyelinating distal neuropathy starting in the legs, with gait disturbance and tremor in the arms as the predominant disabling symptoms. 1
Key Clinical Features:
- Sensory symptoms: Distal numbness, paresthesias, prominent deep sensory ataxia
- Motor symptoms: Distal weakness (less prominent than sensory features)
- Ataxia: Gait instability, upper limb tremor
- Distribution: Symmetric, distal-to-proximal gradient
- Progression: Slowly progressive over years
- Male predominance
- Estimated prevalence: 0.28 per 100,000 population in Japan 3
Diagnostic Criteria
Essential Diagnostic Elements:
1. Serological Testing:
- Anti-MAG antibody titer ≥10,000 BTU (Bühlmann titration units) provides 100% specificity for typical anti-MAG neuropathy 4
- Titer ≥1,500 BTU offers 96% specificity and reduces likelihood of immune-treatable CIDP 4
- IgM monoclonal gammopathy on serum protein electrophoresis with immunofixation
- Mass-Fix (mass spectrophotometry) superior to standard SPIEP for detecting IgM gammopathy 4
2. Electrodiagnostic Studies:
- Prolonged distal latencies (hallmark finding)
- Demyelinating pattern: may show demyelinating, axonal, or mixed patterns 1
- Distal-predominant demyelination with secondary axonal loss
- Caution: Nerves can become inexcitable in advanced disease, masking demyelinating abnormalities 5
3. Additional Testing:
- Complete blood count, comprehensive metabolic panel
- Cerebrospinal fluid analysis: typically elevated protein
- Serum and urine protein electrophoresis with immunofixation
- Nerve biopsy (if diagnosis uncertain): shows widely spaced myelin on electron microscopy 3
- Bone marrow biopsy to exclude B-cell proliferative disorders 6
Treatment Recommendations
First-Line Treatment:
IVIG and rituximab are the most frequently used treatments, though evidence shows benefit in only approximately 50% of patients. 1
- Rituximab: Most common first-line agent
Emerging Therapies:
Bruton tyrosine kinase (BTK) inhibitors show promise, particularly in MYD88-mutant cases:
- Tirabrutinib (second-generation BTK inhibitor): for rituximab-refractory cases 1
- Ibrutinib/Zanubrutinib: Emerging options 4
- Particularly effective in patients with MYD88L265P mutation 7, 3
Therapies with Limited/No Benefit:
Standard CIDP treatments are ineffective in anti-MAG neuropathy: 8
- Corticosteroids: Generally ineffective 3
- IVIG alone: Response rate only 49% 1
- Plasma exchange (TPE): Category III indication (Grade 1C) - may produce only transient response 1
Special Considerations:
For patients with immunologic manifestations (e.g., anti-MAG neuropathy) in Waldenström's macroglobulinemia, rituximab single-agent therapy should be considered, particularly in frail patients less likely to tolerate chemoimmunotherapy. 9
Treatment Algorithm
For progressive, functionally impairing disease:
- Confirm diagnosis: Anti-MAG titer ≥10,000 BTU + IgM gammopathy + typical clinical/electrodiagnostic features
- Test for MYD88L265P mutation (guides BTK inhibitor use)
- First-line: Rituximab (standard or low-dose individualized regimen)
- Monitor: Target ≥50-60% IgM reduction
- If rituximab-refractory: BTK inhibitors (tirabrutinib, ibrutinib, zanubrutinib) - especially if MYD88-mutant
- Avoid: Standard CIDP therapies (steroids, IVIG monotherapy, plasma exchange as primary treatment)
Key Pitfalls to Avoid
- Do not treat as CIDP: Standard CIDP therapies are ineffective 8
- Do not rely on intermediate anti-MAG titers (1:320-1:1000): Can occur in CIDP; use ≥1,500 BTU cutoff 4
- Do not use plasma exchange as primary therapy: Only produces transient responses 1
- Do not overlook IgM gammopathy: Use Mass-Fix for superior detection 4
- Do not delay BTK inhibitor consideration: Particularly effective in MYD88-mutant, rituximab-refractory cases 1, 7
- Do not treat asymptomatic or non-progressive disease: Reserve treatment for functionally impairing, progressive neuropathy 5
Prognosis & Monitoring
- Disease can remain indolent for years then enter progressive phase 5
- Treatment trials may require 2 years duration to demonstrate efficacy 5
- Optimal outcome measures: Neuropathy Impairment Score of Lower Extremities (NIS-LL) + Lower Limb Function (LLF) score 5
- Monitor INCAT disability scores and summated CMAP for treatment response 4
- Presence of IgM gammopathy (even without high anti-MAG titers) correlates with worse treatment response 4